Does Repaglinide Interact with Tecovirimat Monohydrate?
Repaglinide and Tecovirimat Monohydrate have a moderate drug interaction according to U.S. FDA drug labeling data. TPOXX increases repaglinide concentration. Monitor blood glucose and hypoglycemic symptoms when co-administered. The mechanism involves tecovirimat is a weak inhibitor of cyp2c8, which metabolizes repaglinide. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Repaglinide Class
- Glinide
- Tecovirimat Monohydrate Class
- Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Repaglinide and Tecovirimat Monohydrate occurs because tecovirimat is a weak inhibitor of cyp2c8, which metabolizes repaglinide. Clinically, this means tpoxx increases repaglinide concentration. monitor blood glucose and hypoglycemic symptoms when co-administered. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Repaglinide and your doctor is considering prescribing Tecovirimat Monohydrate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider